Pharmacokinetics and Non-Clinical Safety Department, Nippon Boehringer Ingelheim Co., Ltd., Kobe, Hyogo, Japan.
Sugiyama Laboratory, RIKEN Baton Zone Program, RIKEN Cluster for Science, Technology and Innovation Hub, Yokohama, Kanagawa, Japan.
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):396-406. doi: 10.1002/psp4.12398. Epub 2019 Mar 19.
Metformin is an important antidiabetic drug and often used as a probe for drug-drug interactions (DDIs) mediated by renal transporters. Despite evidence supporting the inhibition of multidrug and toxin extrusion proteins as the likely DDI mechanism, the previously reported physiologically-based pharmacokinetic (PBPK) model required the substantial lowering of the inhibition constant values of cimetidine for multidrug and toxin extrusion proteins from those obtained in vitro to capture the clinical DDI data between metformin and cimetidine. We constructed new PBPK models in which the transporter-mediated uptake of metformin is driven by a constant membrane potential. Our models successfully captured the clinical DDI data using in vitro inhibition constant values and supported the inhibition of multidrug and toxin extrusion proteins by cimetidine as the DDI mechanism upon sensitivity analysis and data fitting. Our refined PBPK models may facilitate prediction approaches for DDI involving metformin using in vitro inhibition constant values.
二甲双胍是一种重要的抗糖尿病药物,常被用作研究肾脏转运体介导的药物相互作用(DDI)的探针。尽管有证据支持多药和毒素外排蛋白的抑制作用可能是 DDI 的机制,但先前报道的基于生理的药代动力学(PBPK)模型需要大量降低西咪替丁对多药和毒素外排蛋白的抑制常数值,以使体外获得的数值与二甲双胍和西咪替丁之间的临床 DDI 数据相吻合。我们构建了新的 PBPK 模型,其中二甲双胍的转运体介导摄取由恒定的膜电位驱动。我们的模型使用体外抑制常数值成功地捕获了临床 DDI 数据,并通过敏感性分析和数据拟合支持西咪替丁抑制多药和毒素外排蛋白作为 DDI 机制。我们的改进的 PBPK 模型可能有助于使用体外抑制常数值预测涉及二甲双胍的 DDI 方法。